argenx
- Country
- ๐ง๐ชBelgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- argenx
- Target Recruit Count
- 240
- Registration Number
- NCT05523167
- Locations
- ๐ฏ๐ต
The University of Tokyo Hospital, Tokyo, Japan
๐ฉ๐ชUniversitatsklinikum Ulm - Standort Oberer Eselsberg, Ulm, Germany
๐ฏ๐ตJuntendo University Hospital - Rheumatology, Tokyo, Japan
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- argenx
- Target Recruit Count
- 51
- Registration Number
- NCT05405361
- Locations
- ๐บ๐ธ
HonorHealth Neurology, Scottsdale, Arizona, United States
๐บ๐ธAustin Neuromuscular Center, Austin, Texas, United States
๐ฆ๐นMedizinische Universitat Wien (Medical University of Vienna), Vienna, Austria
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT05374590
- Locations
- ๐ณ๐ฑ
Leids Universitair Medisch Centrum, Leiden, Netherlands
๐บ๐ธAnn and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
๐ต๐ฑWielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- argenx
- Target Recruit Count
- 98
- Registration Number
- NCT05267600
- Locations
- ๐บ๐ธ
Investigator site 121 - US0010092, Redwood City, California, United States
๐บ๐ธInvestigator site 115 - US0010157, Jackson, Mississippi, United States
๐บ๐ธInvestigator site 34 - US0010182, Houston, Texas, United States
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- argenx
- Target Recruit Count
- 54
- Registration Number
- NCT05225675
- Locations
- ๐บ๐ธ
HonorHealth Research Institute-Neuroscience Research, Maitland, Florida, United States
๐บ๐ธGeorge Washington Medical Faculty Associates, Washington, District of Columbia, United States
๐บ๐ธUniversity of South Florida Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- argenx
- Target Recruit Count
- 36
- Registration Number
- NCT05163834
- Locations
- ๐ณ๐ฑ
Investigator site 1, Groningen, Netherlands
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- argenx
- Target Recruit Count
- 69
- Registration Number
- NCT04980495
- Locations
- ๐บ๐ธ
Investigator Site 9 - 0010006, Boca Raton, Florida, United States
๐บ๐ธInvestigator Site 17 - US0010012, Philadelphia, Pennsylvania, United States
๐บ๐ธInvestigator Site 10 - US0010007, Carlsbad, California, United States
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT04833894
- Locations
- ๐บ๐ธ
Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
๐บ๐ธUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
๐บ๐ธUniversity of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia, United States
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- argenx
- Target Recruit Count
- 183
- Registration Number
- NCT04818671
- Locations
- ๐ฉ๐ช
Investigator Site 26 - DE490009, Mรผnster, Germany
๐ฌ๐ชInvestigator Site 1 - GEO9950001, Tbilisi, Georgia
๐ฌ๐ชInvestigator Site 33 - GEO9950016, Tbilisi, Georgia
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 173
- Registration Number
- NCT04812925
- Locations
- ๐น๐ณ
Investigator site 2160002, Tunis, Tunisia
๐จ๐ฑInvestigator site 560002, Santiago, Chile
๐ฆ๐บInvestigator Site 0610003, West Perth, Australia